Characterization of Ebola Virus-Associated Eye Disease.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
04 01 2021
Historique:
entrez: 5 1 2021
pubmed: 6 1 2021
medline: 16 3 2021
Statut: epublish

Résumé

Survivors of Ebola virus disease (EVD) may experience ocular sequelae. Comparison with antibody-negative individuals from the local population is required to characterize the disease. To assess features of ophthalmic disease specific to EVD. This baseline cross-sectional analysis of survivors of EVD and their close contacts was conducted within PREVAIL III, a 5-year, longitudinal cohort study. Participants who enrolled at John F. Kennedy Medical Center in Liberia, West Africa from June 2015 to March 2016 were included in this analysis. Close contacts were defined as household members or sex partners of survivors of EVD. Data were analyzed from July 2016 to July 2020. All participants, both survivors and close contacts, underwent testing of IgG antibody levels against Ebola virus surface glycoprotein. Ocular symptoms, anterior and posterior ophthalmologic examination findings, and optical coherence tomography images were compared between antibody-positive survivors and antibody-negative close contacts. A total of 564 antibody-positive survivors (320 [56.7%] female; mean [SD] age, 30.3 [14.0] years) and 635 antibody-negative close contacts (347 [54.6%] female; mean [SD] age, 25.8 [15.5] years) were enrolled in this study. Survivors were more likely to demonstrate color vision deficit (28.9% vs 19.0%, odds ratio [OR], 1.6; 95% CI, 1.2-2.1) and lower intraocular pressure (12.4 vs 13.5 mm Hg; mean difference, -1.2 mm Hg; 95% CI, -1.6 to -0.8 mm Hg) compared with close contacts. Dilated fundus examination revealed a higher percentage of vitreous cells (7.8% vs 0.5%; OR, 16.6; 95% CI, 5.0-55.2) and macular scars (4.6% vs 1.6%; OR, 2.8; 95% CI, 1.4-5.5) in survivors than in close contacts. Uveitis was present in 26.4% of survivors and 12.1% of close contacts (OR, 2.4; 95% CI, 1.8-3.2). Among all participants with uveitis, survivors were more likely than close contacts to have intermediate uveitis (34.2% vs 6.5% of all cases; OR, 7.8; 95% CI, 3.1-19.7) and had thicker mean central subfield thickness on optical coherence tomography (222 vs 212 μm; mean difference, 14.4 μm; 95% CI, 1.9-26.9 μm). In this cross-sectional study, survivors of EVD had a distinct spectrum of ocular and neuro-ophthalmologic findings compared with close contacts that potentially require medical and surgical treatment.

Identifiants

pubmed: 33399856
pii: 2774580
doi: 10.1001/jamanetworkopen.2020.32216
pmc: PMC7786253
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2032216

Subventions

Organisme : NEI NIH HHS
ID : K12 EY015025
Pays : United States
Organisme : NEI NIH HHS
ID : L30 EY024746
Pays : United States

Références

Emerg Infect Dis. 2017 Jul;23(7):1102-1109
pubmed: 28628441
Ann Afr Med. 2017 Oct-Dec;16(4):170-174
pubmed: 29063900
JAMA Ophthalmol. 2018 Jun 1;136(6):689-693
pubmed: 29800941
N Engl J Med. 2015 Jun 18;372(25):2423-7
pubmed: 25950269
Lancet Infect Dis. 2016 Mar;16(3):331-8
pubmed: 26725449
Bull World Health Organ. 2007 Nov;85(11):867-72
pubmed: 18038077
J Infect Dis. 1999 Feb;179 Suppl 1:S13-4
pubmed: 9988158
EBioMedicine. 2018 Apr;30:217-224
pubmed: 29622497
Am J Ophthalmol. 2017 Mar;175:114-121
pubmed: 27998698
N Engl J Med. 2017 Oct 12;377(15):1438-1447
pubmed: 29020589
N Engl J Med. 2019 Mar 7;380(10):924-934
pubmed: 30855742
Ophthalmology. 2017 Feb;124(2):170-177
pubmed: 27914832

Auteurs

Allen O Eghrari (AO)

Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland.

Rachel J Bishop (RJ)

National Institutes of Health, Bethesda, Maryland.

Robin D Ross (RD)

Global Retina Institute, Scottsdale, Arizona.

Bionca Davis (B)

Division of Biostatistics, University of Minnesota, Minneapolis.

Jemma Larbelee (J)

Redemption Hospital, Monrovia, Liberia.

Fred Amegashie (F)

Liberian Ministry of Health, Monrovia, Liberia.

Robert F Dolo (RF)

New Sight Eye Centre, Paynesville, Liberia.

S Grace Prakalapakorn (SG)

Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina.

Catherine Gaisie (C)

New Sight Eye Centre, Paynesville, Liberia.

Catherine Gargu (C)

Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.

Yassah Sosu (Y)

Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.

Jennie Sackor (J)

Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.

Precious Z Cooper (PZ)

Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.

Augustine Wallace (A)

Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.

Ruth Nyain (R)

Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.

Maima Gray (M)

Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.

Famatta Kamara (F)

Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia.

Bryn Burkholder (B)

Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland.

Christopher J Brady (CJ)

University of Vermont School of Medicine, Burlington.

Vincent Ray (V)

Department of Ophthalmology, California Pacific Medical Center, San Francisco.

Kirstin L Tawse (KL)

Department of Ophthalmology, Kaiser Permanente, Denver, Colorado.

Ian Yeung (I)

National Institutes of Health, Bethesda, Maryland.

James D Neaton (JD)

Division of Biostatistics, University of Minnesota, Minneapolis.

Elizabeth S Higgs (ES)

National Institutes of Health, Bethesda, Maryland.

H Clifford Lane (HC)

National Institutes of Health, Bethesda, Maryland.

Cavan Reilly (C)

Division of Biostatistics, University of Minnesota, Minneapolis.

Michael C Sneller (MC)

National Institutes of Health, Bethesda, Maryland.

Mosoka P Fallah (MP)

National Public Health Institute of Liberia, Monrovia, Liberia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH